Zynteglo Funding Rejection Sets "Dangerous Precedent" For Gene Therapies In UK
Bluebird Bio Rails Against Negative Reimbursement Decision
bluebird is "shocked and disappointed" at the draft negative reimbursement decision on Zynteglo in UK but measures outlined in the NICE methods review could change fortunes of gene and cell therapies if taken forward.
You may also be interested in...
Last Chance To Influence Changes To NICE Methods & Processes In England
Companies selling gene therapies and other high-cost, long-term treatments may be disappointed but unsurprised to learn that NICE will not immediately introduce any change to discount rates, which are used in health technology appraisals to better understand the long-term costs and benefits.
Tough Times In Europe For Gene Therapy Companies
bluebird bio's decision to wind down commercial initiatives for its gene therapy business in Europe is a blow for the sector in the region as a whole.
Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.